The HPV vaccination drive in India is a landmark public-health intervention targeting cervical cancer — the second most common cancer among Indian women. The Human Papillomavirus (HPV) is responsible for nearly 99% of cervical cancer cases, with two high-risk subtypes — HPV 16 and HPV 18 — causing approximately 70% of global cervical cancers. India's indigenous quadrivalent vaccine CERVAVAC, launched in 2022 by the Serum Institute of India (SII), along with the Union Budget 2024-25 announcement of a national HPV vaccination programme, marks a decisive shift in India's cancer-control architecture.
For UPSC aspirants, HPV vaccination is a high-yield topic linking GS2 (Health), GS3 (Science & Technology), and issues of public-health financing, women's health, and indigenous R&D.
Understanding HPV and Cervical Cancer
What is HPV?
Human Papillomavirus (HPV) is a group of more than 200 related DNA viruses, of which around 40 types infect the anogenital tract. HPV is primarily transmitted through sexual contact and is the most common sexually transmitted infection worldwide.
- Low-risk types (HPV 6, 11) — cause genital warts
- High-risk types (HPV 16, 18, 31, 33, 45, 52, 58) — cause cancers
- HPV 16 + HPV 18 — together responsible for ~70% of cervical cancers
Cancers Linked to HPV
| Cancer | HPV Contribution |
|---|---|
| Cervical cancer | ~99% |
| Anal cancer | ~90% |
| Oropharyngeal cancer | ~70% |
| Vaginal cancer | ~75% |
| Vulvar cancer | ~70% |
| Penile cancer | ~60% |
India's Cervical Cancer Burden
- ~1.25 lakh new cases of cervical cancer are diagnosed annually in India
- ~77,000 deaths every year (ICMR-NCRP estimate)
- India accounts for nearly 1 in 5 global cervical cancer deaths
- Peak age of occurrence: 40–55 years
- Most cases detected at late stages due to poor screening coverage (<5% women screened)
CERVAVAC — India's Indigenous HPV Vaccine
Launch
CERVAVAC is India's first indigenously developed quadrivalent HPV vaccine, launched on September 1, 2022 by the Department of Biotechnology (DBT) and Serum Institute of India (SII) in partnership with the Bill & Melinda Gates Foundation.
Key Features
| Feature | Details |
|---|---|
| Manufacturer | Serum Institute of India (SII), Pune |
| Type | Quadrivalent (protects against HPV 6, 11, 16, 18) |
| Technology | Recombinant Virus-Like Particle (VLP) |
| Regulatory approval | DCGI, July 2022 |
| Price per dose | ~Rs. 300–400 (vs. ~Rs. 3,000–4,000 for imported vaccines) |
| Target age | Girls 9–14 years (2 doses) |
| Catch-up age | 15–26 years (3 doses) |
Why CERVAVAC Matters
- Affordability — ~10× cheaper than imported Gardasil/Cervarix
- Indigenous capacity — reduces import dependence for a key public-health vaccine
- Self-reliance (Atmanirbhar Bharat) in biotech manufacturing
- Scalability — SII's capacity can meet India's ~5 crore target cohort
Imported HPV Vaccines Available in India
| Vaccine | Manufacturer | Valency | Protects Against |
|---|---|---|---|
| Gardasil | Merck (MSD) | Quadrivalent | HPV 6, 11, 16, 18 |
| Gardasil 9 | Merck (MSD) | Nonavalent | HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Cervarix | GlaxoSmithKline | Bivalent | HPV 16, 18 |
| CERVAVAC | Serum Institute | Quadrivalent | HPV 6, 11, 16, 18 |
National HPV Vaccination Programme
Union Budget 2024–25 Announcement
In the Interim Budget 2024–25 (February 1, 2024), Finance Minister Nirmala Sitharaman announced that the government would encourage HPV vaccination for girls aged 9–14 years to prevent cervical cancer. This was reiterated in the Full Budget (July 2024) and operational roll-out plans were detailed in subsequent health policy documents.
Implementation Framework
- Integration with Mission Indradhanush / Universal Immunization Programme (UIP) — HPV to be added as a routine vaccine
- Delivery platform — schools (Class 5–9) and health-sub-centres
- Target cohort — approximately 7 crore girls in the 9–14 age group
- Lead agency — Ministry of Health & Family Welfare, with NTAGI (National Technical Advisory Group on Immunisation) recommendation
- Phased rollout — beginning with high-burden states and gradually expanding nationally through 2026
Dosage Schedule
| Age Group | Doses | Interval |
|---|---|---|
| 9–14 years | 2 doses | 0, 6 months |
| 15–26 years | 3 doses | 0, 2, 6 months |
| Immunocompromised | 3 doses | Regardless of age |
WHO's SAGE (Strategic Advisory Group of Experts) recommends a single-dose schedule as sufficient for girls 9–20 years — India's NTAGI is evaluating adoption.
State-Level HPV Programmes
Several Indian states ran pilot HPV vaccination programmes before the national announcement:
| State | Year | Coverage |
|---|---|---|
| Sikkim | 2018 | First state; girls Class 6 |
| Punjab | 2019 | Pilot in Mansa, Bathinda |
| Delhi | 2022–23 | Selected schools pilot |
| Maharashtra | 2023 | Free HPV vaccination for girls (limited districts) |
| Karnataka | 2024 | Public-sector rollout in select districts |
Sikkim recorded >95% coverage in its school-based model — demonstrating that population-level uptake is achievable with strong state commitment.
Global Context
- WHO Global Strategy (2020) — targets elimination of cervical cancer by 2030 with "90-70-90" goals:
- 90% of girls vaccinated by age 15
- 70% of women screened with high-performance test by age 35 and 45
- 90% of women with cervical disease treated
- Australia — first country on track to eliminate cervical cancer (by 2028) via HPV vaccination + screening
- Rwanda, Bhutan, UK, Malaysia — demonstrated successful national programmes
- US, Canada, most of EU — vaccination routine for both boys and girls (gender-neutral)
Challenges in India
1. Awareness and Acceptance
- Vaccine hesitancy among parents, particularly in rural areas
- Cultural sensitivities around discussing sexual transmission
- Misinformation linking HPV vaccine to infertility (debunked)
2. Historical Setback
- A 2009–2010 ICMR demonstration project in Andhra Pradesh and Gujarat was suspended after alleged adverse events
- Parliamentary Standing Committee (2013) raised concerns on consent procedures — not vaccine safety
- The episode created lasting hesitancy; scientific consensus remains: HPV vaccines are safe and effective
3. Infrastructure
- Cold-chain strengthening required
- Integration with school health programmes needs coordination with education departments
- Training of ASHA, ANM, and school health workers
4. Screening Gap
- Vaccination alone is insufficient — HPV DNA testing or VIA (Visual Inspection with Acetic Acid) screening must be scaled
- Only ~2% of Indian women are screened regularly
Complementary Measures
- Cervical cancer screening via VIA/HPV DNA testing for women 30–65
- Ayushman Bharat — cervical cancer treatment coverage under PM-JAY
- Mission Indradhanush — platform integration
- National Cancer Control Programme — infrastructure for tertiary treatment
UPSC Relevance
GS2 (Health): Public health interventions, universal immunisation, women's health, health-financing.
GS3 (Science & Technology): Indigenous vaccine R&D, biotechnology, recombinant vaccine technology.
Key Prelims facts:
- HPV = Human Papillomavirus (DNA virus, >200 types)
- HPV 16 and 18 cause ~70% of cervical cancers
- Cervical cancer: 2nd most common cancer among Indian women
- India's annual cases: ~1.25 lakh; deaths: ~77,000
- CERVAVAC: launched September 2022; Serum Institute of India
- CERVAVAC: Quadrivalent (HPV 6, 11, 16, 18); VLP technology
- CERVAVAC price: ~Rs. 300–400 per dose
- Target age: 9–14 years (2 doses, 6 months apart)
- Announced in Union Budget 2024–25
- First state to introduce: Sikkim (2018)
- WHO goal: Eliminate cervical cancer by 2030 ("90-70-90")
- Imported vaccines: Gardasil, Gardasil 9, Cervarix
- Integration platform: Universal Immunization Programme / Mission Indradhanush
- Lead agency: MoHFW; advisory: NTAGI
Tell Google you want more of this.
Add Anantam IAS as a preferred sourceOne tap, and this site shows up more often in your own Top Stories, AI Overviews and AI Mode. Remove it any time.
